Precision medicine for prostate cancer

Myria Galazi; Alejo Rodriguez-Vida; Tony Ng; Malcolm Mason; Simon Chowdhury

doi:10.1586/14737140.2014.972948

Precision medicine for prostate cancer

Myria Galazi, Alejo Rodriguez-Vida, Tony Ng, Malcolm Mason, Simon Chowdhury^*

^*Corresponding author for this work

Cell Imaging

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.

Original language	English
Pages (from-to)	1305-1315
Number of pages	11
Journal	EXPERT REVIEW OF ANTICANCER THERAPY
Volume	14
Issue number	11
Early online date	30 Oct 2014
DOIs	https://doi.org/10.1586/14737140.2014.972948
Publication status	Published - 1 Nov 2014

Keywords

androgen receptor
castration-resistant prostate cancer
ETS fusion gene rearrangements
PI3K/AKT/mTOR pathway
precision medicine
PTEN loss

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2014.972948

Cite this

@article{27e9bb4817674b039435e5a7691406f0,

title = "Precision medicine for prostate cancer",

abstract = "Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.",

keywords = "androgen receptor, castration-resistant prostate cancer, ETS fusion gene rearrangements, PI3K/AKT/mTOR pathway, precision medicine, PTEN loss",

author = "Myria Galazi and Alejo Rodriguez-Vida and Tony Ng and Malcolm Mason and Simon Chowdhury",

year = "2014",

month = nov,

day = "1",

doi = "10.1586/14737140.2014.972948",

language = "English",

volume = "14",

pages = "1305--1315",

journal = "EXPERT REVIEW OF ANTICANCER THERAPY",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "11",

}

TY - JOUR

T1 - Precision medicine for prostate cancer

AU - Galazi, Myria

AU - Rodriguez-Vida, Alejo

AU - Ng, Tony

AU - Mason, Malcolm

AU - Chowdhury, Simon

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.

AB - Metastatic castration-resistant prostate cancer remains a lethal disease despite considerable progress in systemic therapy over the past decade. The recent advances in genomic sequencing have improved the molecular classification of prostate cancer. The translation of genomic data into clinically relevant prognostic and predictive biomarkers to guide therapy is still in its infancy and therapies for castration-resistant prostate cancer are still used empirically. We discuss these genomic aberrations in more detail, focusing on androgen receptor signaling, ETS transcription factor gene rearrangements and PTEN loss. The incorporation of this genomic data within early phase clinical trials is evolving and may prove significant in advancing personalized care in prostate cancer.

KW - androgen receptor

KW - castration-resistant prostate cancer

KW - ETS fusion gene rearrangements

KW - PI3K/AKT/mTOR pathway

KW - precision medicine

KW - PTEN loss

UR - http://www.scopus.com/inward/record.url?scp=84910045480&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.972948

DO - 10.1586/14737140.2014.972948

M3 - Article

C2 - 25354871

AN - SCOPUS:84910045480

SN - 1473-7140

VL - 14

SP - 1305

EP - 1315

JO - EXPERT REVIEW OF ANTICANCER THERAPY

JF - EXPERT REVIEW OF ANTICANCER THERAPY

IS - 11

ER -

Precision medicine for prostate cancer

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this